13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      HIPODERMÓCLISE PARA TRATAMENTOS NÃO CONVENCIONAIS EM PEDIATRIA: REVISÃO INTEGRATIVA Translated title: HIPODERMOCLISIS PARA TRATAMIENTOS NO CONVENCIONALES EN PEDIATRÍA: REVISIÓN INTEGRATIVA Translated title: HYPODERMOCLYSIS FOR UNCONVENTIONAL PEDIATRIC TREATMENTS: AN INTEGRATIVE REVIEW

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMO Objetivo: descrever o uso da hipodermóclise em tratamentos pediátricos não convencionais. Método: revisão integrativa, com período amostral de 2010 a 2018, em cinco bases de dados. Dois revisores independentes procederam à seleção dos artigos. Após foi realizada avaliação pelo nível de evidência, segundo Instituto Joanna Briggs. Resultados: foram selecionados seis artigos internacionais, com evidência de nível 1 e 3. As doenças e situações não-convencionais para o tratamento via hipodermóclise foram: artrite idiopática juvenil poliarticular; prevenção de hiponatremia na restrição de fluidos; sedação em tratamento odontológico; desordens reumáticas; antibioticoterapia e hipertensão arterial pulmonar refratária. Conclusão: o procedimento constitui-se como opcional efetivo e seguro para administração de medicamentos em crianças, justificada devido à minimização da intensidade da dor e proteção do estresse da criança, família e equipe de enfermagem. Contudo, são necessárias mais pesquisas para fundamentá-lo cientificamente, e para implementação na prática profissional.

          Translated abstract

          RESUMEN Objetivo: Describir el uso de la hipodermoclisis en tratamientos pediátricos no convencionales. Método: Revisión integrativa, con período muestral de 2010 a 2018, en cinco bases de datos. Dos revisores independientes se ocuparon de seleccionar los artículos. Luego se realizó una evaluación por nivel de evidencia, según Instituto Joanna Briggs. Resultados: Fueron seleccionados seis artículos internacionales, con evidencia de nivel 1 y 3. Las enfermedades y situaciones no convencionales para tratamiento vía hipodermoclisis fueron: artritis idiopática juvenil poliarticular; prevención de hiponatremia en la restricción de fluidos; sedación en tratamiento odontológico; desórdenes reumáticos; antibioticoterapia e hipertensión pulmonar refractaria. Conclusión: El procedimiento se constituye como opción efectiva y segura para la administración de medicamentos en niños, justificada por la mínima intensidad de dolor y por proteger al niño, la familia y al equipo de enfermería del estrés. Sin embargo, serán necesarias más investigaciones para fundamentarlo científicamente, e implementarlo en la práctica profesional.

          Translated abstract

          ABSTRACT Objective: to describe the use of hypodermoclysis in unconventional pediatric treatments. Method: an integrative review, with sampling period from 2010 to 2018, in five databases. Two independent reviewers selected the articles. Next, an evaluation of the level of evidence wasperformed, according to the Joanna Briggs Institute. Results: Six international articles were selected, with levels of evidence 1 and 3. The unconventional diseases and situations for treatment via hypodermoclysis were: polyarticular juvenile idiopathic arthritis; prevention of hyponatremia during fluid restriction; sedation in dental treatment; rheumatic disorders; antibiotic therapy and refractory pulmonary arterial hypertension. Conclusion: the procedure is an effective and safe option for the administration of medications in children, justified due to the minimization of pain intensity and the protection of the child, familyand nursing staff from stress. However, more research is needed to substantiate it scientifically, and for its implementation in the professional practice.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

          Systematic reviews and meta-analyses are essential to summarize evidence relating to efficacy and safety of health care interventions accurately and reliably. The clarity and transparency of these reports, however, is not optimal. Poor reporting of systematic reviews diminishes their value to clinicians, policy makers, and other users. Since the development of the QUOROM (QUality Of Reporting Of Meta-analysis) Statement--a reporting guideline published in 1999--there have been several conceptual, methodological, and practical advances regarding the conduct and reporting of systematic reviews and meta-analyses. Also, reviews of published systematic reviews have found that key information about these studies is often poorly reported. Realizing these issues, an international group that included experienced authors and methodologists developed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) as an evolution of the original QUOROM guideline for systematic reviews and meta-analyses of evaluations of health care interventions. The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram. The checklist includes items deemed essential for transparent reporting of a systematic review. In this Explanation and Elaboration document, we explain the meaning and rationale for each checklist item. For each item, we include an example of good reporting and, where possible, references to relevant empirical studies and methodological literature. The PRISMA Statement, this document, and the associated Web site (http://www.prisma-statement.org/) should be helpful resources to improve reporting of systematic reviews and meta-analyses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

            Objective This report aims to determine the safety, pharmacokinetics (PK) and efficacy of subcutaneous golimumab in active polyarticular-course juvenile idiopathic arthritis (polyJIA). Methods In this three-part randomised double-blinded placebo-controlled withdrawal trial, all patients received open-label golimumab (30 mg/m2 of body surface area; maximum: 50 mg/dose) every 4 weeks together with weekly methotrexate during Part 1 (weeks 0–16). Patients with at least 30% improvement per American College of Rheumatology Criteria for JIA (JIA ACR30) in Part 1 entered the double-blinded Part 2 (weeks 16–48) after 1:1 randomisation to continue golimumab or start placebo. In Part 3, golimumab was continued or could be restarted as in Part 1. The primary outcome was JIA flares in Part 2; secondary outcomes included JIA ACR50/70/90 responses, clinical remission, PK and safety. Results Among 173 patients with polyJIA enrolled, 89.0% (154/173) had a JIA ACR30 response and 79.2%/65.9%/36.4% demonstrated JIA ACR50/70/90 responses in Part 1. At week 48, the primary endpoint was not met as treatment groups had comparable JIA flare rates (golimumab vs placebo: 32/78=41% vs 36/76=47%; p=0.41), and rates of clinical remission were comparable (golimumab vs placebo: 10/78=12.8% vs 9/76=11.8%). Adverse event and serious adverse event rates were similar in the treatment groups during Part 2. Injection site reactions occurred with <1% of all injections. PK analysis confirmed adequate golimumab dosing for polyJIA. Conclusion Although the primary endpoint was not met, golimumab resulted in rapid, clinically meaningful, improvement in children with active polyJIA. Golimumab was well tolerated, and no unexpected safety events occurred. Clinical Trial Registration NCT01230827; Results.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.

              To evaluate the efficacy and tolerability of subcutaneous (SC) treprostinil, a prostacyclin analogue, in young children with refractory pulmonary arterial hypertension. Eight children (median age, 4 years) received SC treprostinil therapy after failure of combined oral treatment (n = 7) or because of severe complications with intravenous epoprostenol (n = 1). Treprostinil was delivered through an SC catheter at gradually increasing doses to an average of 40 ng/kg/min, depending on the presence of adverse effects. Seven patients demonstrated early significant improvement (in functional class, hemodynamics, and/or 6-minute walk distance; P <.05), and 6 had a sustained good response. Site pain could be effectively managed in all but one child. Treprostinil may be a potentially valuable rescue therapy in children with refractory pulmonary arterial hypertension, but further study in a larger number of patients is needed. Copyright © 2011 Mosby, Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                ce
                Cogitare Enfermagem
                Cogitare enferm.
                Universidade Federal do Paraná (Curitiba, PR, Brazil )
                1414-8536
                2176-9133
                2019
                : 24
                : e61546
                Affiliations
                [5] Curitiba Paraná orgnameUniversidade Positivo Brazil
                [2] Curitiba Paraná orgnameUniversidade Federal do Paraná orgdiv1Programa de Pós-graduação em Enfermagem Profissional Brazil
                [4] Curitiba Paraná orgnameUniversidade Federal do Paraná Brazil
                [1] Curitiba Paraná orgnameUniversidade Federal do Paraná Brazil
                [3] Curitiba Paraná orgnameUniversidade Federal do Paraná Brazil
                [6] Curitiba Paraná orgnameUniversidade Federal do Paraná Brazil
                Article
                S1414-85362019000100512 S1414-8536(19)02400000512
                10.5380/ce.v24i0.61546
                e730cd6c-95b8-4711-851a-fa8ab3250bfc

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 14 August 2018
                : 13 August 2019
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 32, Pages: 0
                Product

                SciELO Revista de Enfermagem

                Categories
                Revisão

                Enfermagem,Revisión,Tecnología,Hipodermoclisis,Salud del Niño,Enfermería,Revisão,Tecnologia,Hipodermóclise,Saúde da Criança,Review,Technology,Hypodermoclysis,Child Health,Nursing

                Comments

                Comment on this article